These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 24619376)

  • 21. Treatment patterns and costs for metastatic renal cell carcinoma patients with private insurance in the United States.
    Geynisman DM; Hu JC; Liu L; Tina Shih YC
    Clin Genitourin Cancer; 2015 Apr; 13(2):e93-100. PubMed ID: 25450038
    [TBL] [Abstract][Full Text] [Related]  

  • 22. We have a new treatment, but you can't afford it.
    Desch CE
    J Natl Compr Canc Netw; 2006 Sep; 4(8):720-3. PubMed ID: 16995283
    [No Abstract]   [Full Text] [Related]  

  • 23. Advanced renal cell carcinoma in Australia, 2015: what should we do?
    Davis ID
    Asia Pac J Clin Oncol; 2014 Dec; 10(4):285-8. PubMed ID: 25392943
    [No Abstract]   [Full Text] [Related]  

  • 24. Cost analysis of cryotherapy for metastatic disease.
    Ray CE
    J Vasc Interv Radiol; 2012 Jun; 23(6):778-9. PubMed ID: 22626268
    [No Abstract]   [Full Text] [Related]  

  • 25. [Ⅳ. Current Economic Issues in Treatment for Metastatic Renal Cell Carcinoma].
    Mizuno R; Oya M
    Gan To Kagaku Ryoho; 2019 Jan; 46(1):50-53. PubMed ID: 30765642
    [No Abstract]   [Full Text] [Related]  

  • 26. Cost-utility of Sunitinib Versus Pazopanib in Metastatic Renal Cell Carcinoma in Canada using Real-world Evidence.
    Nazha S; Tanguay S; Kapoor A; Jewett M; Kollmannsberger C; Wood L; Bjarnason GAG; Heng D; Soulières D; Reaume MN; Basappa N; Lévesque E; Dragomir A
    Clin Drug Investig; 2018 Dec; 38(12):1155-1165. PubMed ID: 30267257
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of sunitinib in metastatic renal cell carcinoma.
    Purmonen TT
    Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):383-93. PubMed ID: 21831017
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness evaluation of sunitinib as first-line targeted therapy for metastatic renal cell carcinoma in Spain.
    Calvo Aller E; Maroto P; Kreif N; González Larriba JL; López-Brea M; Castellano D; Martí B; Díaz Cerezo S
    Clin Transl Oncol; 2011 Dec; 13(12):869-77. PubMed ID: 22126730
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nivolumab in the Treatment of Metastatic Renal Cell Carcinoma: A Cost-Utility Analysis.
    Raphael J; Sun Z; Bjarnason GA; Helou J; Sander B; Naimark DM
    Am J Clin Oncol; 2018 Dec; 41(12):1235-1242. PubMed ID: 29727313
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland.
    Purmonen T; Martikainen JA; Soini EJ; Kataja V; Vuorinen RL; Kellokumpu-Lehtinen PL
    Clin Ther; 2008 Feb; 30(2):382-92. PubMed ID: 18343276
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The National Institute of Health and Clinical Excellence rejects new treatments for renal cell cancer: Cinderella's invitation is cancelled.
    Eisen T
    BJU Int; 2008 Dec; 102(11):1491-2. PubMed ID: 19007367
    [No Abstract]   [Full Text] [Related]  

  • 32. Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma.
    Benedict A; Figlin RA; Sandström P; Harmenberg U; Ullén A; Charbonneau C; Sandin R; Remák E; Hariharan S; Négrier S
    BJU Int; 2011 Sep; 108(5):665-72. PubMed ID: 21265994
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Medicaid Expansion Did not Improve Time to Treatment for Young Patients With Metastatic Renal Cell Carcinoma.
    Desai AS; Pham M; Weiner AB; Siddiqui MR; Driscoll C; Jain-Poster K; Ko OS; Vo A; Kundu SD
    Clin Genitourin Cancer; 2020 Aug; 18(4):e386-e390. PubMed ID: 32280026
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence, predictors, costs, and outcome of renal cell carcinoma after kidney transplantation: USRDS experience.
    Hurst FP; Jindal RM; Graham LJ; Falta EM; Elster EA; Stackhouse GB; Agodoa LY; Lentine KL; Salifu MO; Abbott KC
    Transplantation; 2010 Oct; 90(8):898-904. PubMed ID: 21248500
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How do cost-effectiveness analyses inform reimbursement decisions for oncology medicines in Canada? The example of sunitinib for first-line treatment of metastatic renal cell carcinoma.
    Chabot I; Rocchi A
    Value Health; 2010; 13(6):837-45. PubMed ID: 20561332
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Economic evaluation of first-line treatments for metastatic renal cell carcinoma: a cost-effectiveness analysis in a health resource-limited setting.
    Wu B; Dong B; Xu Y; Zhang Q; Shen J; Chen H; Xue W
    PLoS One; 2012; 7(3):e32530. PubMed ID: 22412884
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom.
    Amdahl J; Diaz J; Sharma A; Park J; Chandiwana D; Delea TE
    PLoS One; 2017; 12(6):e0175920. PubMed ID: 28636648
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness and reimbursement issues in renal cell carcinoma.
    Gilewski T; Vogelzang NJ
    Semin Oncol; 1989 Feb; 16(1 Suppl 1):20-6. PubMed ID: 2493161
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patterns of practice and pharmacoeconomic analysis of the management of patients with metastatic renal cell carcinoma (mRCC) in Greece--the CRISIS study. A retrospective analysis by the Hellenic Genitourinary Cancer Group (HGUCG).
    Tsironis G; Koutsoukos K; Athanasakis K; Tsiara A; Tzannis K; Gerolympou M; Visvikis A; Oikonomopoulos G; Kollia A; Giannopoulou E; Dimitra M; Kostouros E; Papatsoris A; Dellis A; Stravodimos K; Varkarakis I; Samantas E; Aravantinos G; Kentepozidis N; Christodoulou C; Bozionelou V; Dimopoulos MA; Bamias A
    Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):491-501. PubMed ID: 30417707
    [No Abstract]   [Full Text] [Related]  

  • 40. Economic burden of renal cell carcinoma among older adults in the targeted therapy era.
    Kale HP; Mays DP; Nadpara PA; Slattum PW; Paul AK; Carroll NV
    Urol Oncol; 2019 Jun; 37(6):356.e19-356.e28. PubMed ID: 30846388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.